Propantheline

Quick links to important sections

Propantheline

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Propantheline

Property Description
Active ingredient Propantheline Bromide
Form Tablet (Oral Dosage Form)
Pharmacological class Anticholinergic / Antispasmodic
Common benefit Relief from smooth muscle spasm
Origin Synthetic (Quaternary Ammonium Compound)

What Type of Medicine is Propantheline? (Identity and Classification)

Propantheline is a synthetic, prescription-only medication whose active component, Propantheline Bromide, belongs to the anticholinergic pharmacological drug class. Chemically, this substance is a quaternary ammonium compound and is classified as a specific muscarinic antagonist. This pharmacological classification is clinically recognized for its ability to modify the involuntary actions controlled by the nervous system.

As an anticholinergic agent, Propantheline functions as a parasympatholytic agent, which means it acts to reduce the influence of the parasympathetic nervous system on certain organs. Propantheline is distinguished by its highly polar quaternary structure, which means its effects are predominantly limited to the peripheral systems, particularly the gut, after oral dosage form administration.


Composition, Form, and General Purpose (Makeup and Benefit)

The medication is composed of the single active ingredient, Propantheline Bromide, combined with necessary solid excipients (inactive ingredients) to create the stable oral tablet for patient consumption. The general purpose of Propantheline is to act as an effective antispasmodic, providing relief from discomfort caused by the involuntary and often painful hyperactivity of smooth muscles.

By facilitating muscarinic receptor blockade, the drug achieves the core benefit of reducing the smooth muscle spasm found in the walls of the gastrointestinal tract and the urinary bladder. This targeted action is useful for calming an overactive internal system, a scenario typically involving uncontrolled contractions or frequent urgency. A dual mechanism, including a specific anticholinergic effect, is used to inhibit gastrointestinal motility and decrease secretions, a property that is highly characteristic of this class of medication.

What side effects are possible with Propantheline?

Possible side effects and safety information

The safety profile of Propantheline Bromide is defined by its anticholinergic action, which leads to officially documented adverse reactions that affect several organ systems, as classified in regulatory documents.

Official Adverse Reaction Profile

The majority of reported adverse reactions are direct pharmacological extensions of the drug's effect. These reactions are typically classified as Common or expected in official labels, or sometimes listed with frequency Not Known across different regulatory texts. System-Organ Classes (SOCs) most often affected include:

  • Ophthalmic Disorders: The anticholinergic action can cause effects such as blurred vision and mydriasis (pupil dilation).
  • Gastrointestinal Disorders: Expected effects include dry mouth (xerostomia), constipation, nausea, and vomiting.
  • Cardiac Disorders: Possible effects on the heart include tachycardia (increased heart rate) and palpitations.
  • Renal and Urinary Disorders: The medication may lead to urinary hesitancy and urinary retention.
  • Dermatologic & Nervous System: Decreased sweating (anhidrosis) and CNS effects like dizziness and drowsiness are also documented.

Serious Safety Considerations and Restrictions

Official regulatory documents detail specific, rare but serious adverse reactions and safety restrictions. The drug’s mydriatic effect can precipitate Acute angle-closure glaucoma in susceptible individuals, and the decrease in sweating carries the risk of heat stroke, particularly in high temperatures. Severe gastrointestinal complications, such as Paralytic ileus or Toxic megacolon (in severe colitis), are also documented risks. For safety, the medication is contraindicated in conditions like obstructive diseases of the urinary or gastrointestinal tract, narrow-angle glaucoma, and Myasthenia Gravis.

Population-Specific Safety Statements

Regulatory labels contain specific warnings for certain groups. Older adults may have increased sensitivity to central nervous system anticholinergic effects and face a heightened risk of conditions like urinary retention and confusion. Caution is also advised for use in patients with known cardiac or renal conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

Propantheline overdose may manifest as an intensification of its usual side effects, progressing to potentially life-threatening systemic collapse, as documented in official regulatory labeling.

Documented Overdose Manifestations

System Official Regulatory Descriptions
Central Nervous Restlessness, excitement, psychotic behavior, delirium, hallucinations, convulsions, and confusion (especially in the elderly).
Anticholinergic Signs Tachycardia, palpitations, severe dry mouth, dilated pupils (Mydriasis), blurred vision, and hot, dry skin with decreased sweating (risk of heat stroke).
Severe Outcomes Respiratory failure due to neuromuscular paralysis, circulatory failure, a fall in blood pressure, and coma are officially documented risks.

Regulatory Mandate for Emergency Action

Any suspected overdose requires that the individual seek immediate medical attention. Official guidance mandates contacting a poison control center or emergency services (e.g., 911) right away, particularly if the person has collapsed, is seizing, or has trouble breathing.

Management procedures described in official labeling include gastric lavage or activated charcoal administration and careful monitoring of vital signs. The drug Physostigmine is the documented antidote for reversing the severe central nervous system and cardiovascular anticholinergic effects of overdose. Supportive care, such as mechanical respiration for paralysis and specific agents like Diazepam for excitement, is also prescribed in regulatory documentation.

Therapeutic Uses of Propantheline

What Propantheline Treats: Main Uses and Benefits

Propantheline is commonly used across domains where additional symptomatic support is needed for conditions marked by heightened physiological stress. Its use is considered relevant in contexts marked by increased discomfort or tension, including when supportive symptom management is appropriate for conditions like ulcers.

The medication is applied in addressing symptom clusters associated with gastrointestinal issues, specific types of bladder problems, and generalized excessive sweating. Its applications are relevant in conditions presenting with disruptive symptom manifestations, such as painful abdominal cramping of Irritable Bowel Syndrome (IBS) and peptic ulcers, along with urological symptoms like urinary urgency and frequency, and the management of hyperhidrosis. It may provide support that helps ease the overall symptom burden.

“Propantheline may be part of symptomatic management to help patients cope more steadily with difficult episodes related to physical discomfort and physiological overactivity.”

Therapeutic Domains

Propantheline may be part of symptomatic management for symptoms related to physical discomfort in the digestive system, addressing painful cramping and spasms associated with IBS and peptic ulcers. It is also used in managing symptoms related to bladder overactivity and for reducing excessive perspiration. By addressing these symptoms, it contributes to improved day-to-day comfort.


Quick Fact: Relief for Symptomatic Discomfort Propantheline is relevant for easing symptoms that create noticeable physiological strain and interfere with daily functioning, applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Propantheline?

Propantheline's eligibility profile is defined by specific contraindications and restrictions outlined in official regulatory documents. Use is strictly contraindicated and prohibited for individuals with conditions that could be worsened by the drug's anticholinergic effects.

Contraindicated Populations (Must Not Use)

Condition Restriction Type
Obstructive uropathy (e.g., bladder neck obstruction) Absolute Contraindication
Obstructive gastrointestinal disease (e.g., paralytic ileus) Absolute Contraindication
Glaucoma (especially narrow-angle) Absolute Contraindication
Severe ulcerative colitis or toxic megacolon Absolute Contraindication
Known hypersensitivity to the drug or components Absolute Contraindication

Restricted and Special Populations

Certain groups require restricted use or caution. Use is advised with caution in patients with hepatic or renal disease and in those with cardiovascular conditions (e.g., tachyarrhythmias).

Age-Related Eligibility: The safety and effectiveness of Propantheline in pediatric patients (children) have not been established. Older adults should use the medicine with caution due to increased sensitivity.

Physiological States: Propantheline is classified as Pregnancy Category C, meaning it should be used during pregnancy only if the potential benefit justifies the potential risk. It is unknown if the drug is excreted in human milk, so caution is advised for nursing mothers.

What should I know about interactions with other medicines?

Propantheline's interaction profile is defined by its anticholinergic activity and its documented effects on gastrointestinal motility. Regulatory information states that co-administration with Pramlintide is officially prohibited due to the risk of synergistic inhibition of gastrointestinal transit.

Drug-Drug Interactions

The combination of Propantheline with other agents having anticholinergic properties, such as Tricyclic Antidepressants or Type 1 Antiarrhythmics, increases the documented risk of additive antimuscarinic side effects. Propantheline’s slowing of gastric emptying is also reported to alter the absorption of numerous oral medicines. This action may lead to increased serum levels for specific formulations, such as slow-dissolving Digoxin tablets, while simultaneously causing reduced and retarded absorption of other drugs, including Paracetamol (Acetaminophen) and Levodopa. Furthermore, the effects of Prokinetic Agents like Metoclopramide are documented to be antagonized by Propantheline.

Timing and Substance Requirements

Specific substances require mandatory time separation. Antacids and Absorbent Antidiarrhoeals must be taken two to three hours apart from Propantheline doses to prevent reduced absorption. To mitigate reduced exposure of the antifungal Ketoconazole, Propantheline must be administered at least two hours after it. Consumption of Alcohol may also increase documented anticholinergic effects such as drowsiness.

Mechanism of Action

Propantheline is a quaternary ammonium anticholinergic agent. Its primary mechanism involves competitive antagonism of muscarinic acetylcholine receptors ( mAChRs), particularly the M2 and M3 subtypes, which are highly expressed on smooth muscle cells and exocrine glands. By occupying these receptors, Propantheline inhibits the binding of the endogenous neurotransmitter acetylcholine ( ACh), thereby interrupting the parasympathetic signaling cascade that initiates smooth muscle contraction and gland secretion. This action results in a reduction of gastrointestinal ( GI) motility and lessens the volume of exocrine secretions, which modulates the effects of cholinergic signaling across the autonomic nervous system. Furthermore, Propantheline decreases the contractility of the bladder detrusor muscle. The resulting mAChR blockade causes a decrease in generalized smooth muscle tone throughout the gut and urinary tract systems. The drug's quaternary structure restricts its ability to cross the blood-brain barrier.

Dosage and Administration Information

Official Administration Guidelines

Propantheline is a medicine administered solely by the oral route in the form of a tablet. Standard guidelines define a precise, time-dependent usage schedule that is based on the four-times-daily (QID) frequency pattern, with dosage adjustments guided by the individual's physiological response. The standard regimen requires taking the tablet before meals and a higher dose at bedtime.

Feature Official Labeled Instruction
Standard Initial Adult Dose 15 mg tablet taken three times daily (TID) before meals, plus 30 mg taken at bedtime (QHS), totaling 75 mg daily.
Timing in Relation to Meals Must be taken on an empty stomach, specifically 30 minutes to at least one hour before meals, as food can reduce drug absorption.
Special Administration Constraint Doses must be separated from antacids or absorbent antidiarrhoeals by two to three hours to prevent reduced absorption.
Maximum Daily Dose Dosage may be adjusted up to a maximum of 120 mg daily.

For administration, tablets should be swallowed whole with water. Dosage can be initiated lower, such as 7.5 mg three times daily, particularly for older adult patients who may be more susceptible to effects. If a dose is missed, standard instructions are to skip the missed dose if it is almost time for the next scheduled dose, and not to take a double dose to compensate. The safety and efficacy of this medication have not been established in the pediatric population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Propantheline

The clinical evaluation of Propantheline is primarily based on research conducted across several decades, including older controlled trials and studies examining patient-reported outcomes. This overview summarizes the structure of the available evidence, including what was studied, the types of findings reported, and what remains uncertain, based solely on authoritative scientific and regulatory sources.

Evidence for Use in Irritable Bowel Syndrome (IBS)

Research exploring how symptoms change over time in IBS has included older, short- to intermediate-term Randomized Controlled Trials (RCTs). Researchers examined patient-reported measures like total symptom scores and outcomes related to achieving an asymptomatic state. However, the evidence is limited because many of these trials utilized modest sample sizes and the methodology does not always meet current high-quality trial standards. Studies frequently evaluated Propantheline when it was administered as part of a combination therapy.

Evidence for Adjunctive Use in Peptic Ulcer Disease

Research explored Propantheline in the context of adjunctive therapy for Peptic Ulcer Disease. The evidence supporting this indication comes from historical controlled trials that were the basis for its initial regulatory recognition. Research examined changes in the rate of gastrointestinal secretions. Since newer drug classes have largely replaced this approach, current modern clinical trial data are not available, and the available research is considered low-level evidence.

Evidence for Bladder Overactivity and Hyperhidrosis

Research for neurogenic bladder dysfunction and urinary urgency includes comparative trials. Findings indicate patterns where Propantheline was observed in some studies to show different patterns of symptomatic outcomes when measured against certain newer treatments. For excessive sweating (hyperhidrosis), the evidence is limited and often based on studies focused on biological processes and case reports, meaning comparative evidence is lacking against contemporary therapies.

Evidence Gaps and Special Populations

The existing research provides limited information for long-term outcomes and durability of findings. The long-term effects are not fully established. Furthermore, the evidence in special populations is inconsistent; while regulatory reference exists for older adults, the extent of effectiveness and safety data in the pediatric population for some indications is limited. Overall, certainty remains low for many applications when evaluated against modern scientific standards.

Key Studies & References

  1. Treatment of irritable bowel syndrome: a review of randomised controlled trials (Review discussing older, limited-quality IBS trials)
  2. Interventions for hyperhidrosis in secondary care: a systematic review and value-of-information analysis (Confirming limited evidence for Propantheline in Hyperhidrosis)

Frequently Asked Questions (FAQ)

Common questions about Propantheline (FAQ)


Q: How long does it take for Propantheline to start working after I take it?

A: Official pharmacological information indicates that Propantheline reaches its highest concentration in the blood, known as peak plasma concentration, in approximately one hour after a person takes an oral dose. The time it takes for a person to feel the effects can vary.


Q: What happens if I take too much Propantheline (overdose symptoms)?

A: If more than the prescribed amount of Propantheline is taken, severe effects may result. Regulatory documents mention that an overdose can lead to a 'curare-like action.' This curare-like action involves neuromuscular blockade and may result in symptoms such as muscular weakness and potential paralysis.


Q: Can Propantheline be crushed or split?

A: Official administration instructions advise that Propantheline tablets should be swallowed whole with water. Official regulatory documents do not provide information on crushing or splitting the tablets.


Q: Can I take Propantheline if I have glaucoma?

A: The official product information lists narrow-angle glaucoma as an absolute contraindication, meaning the drug is generally prohibited for patients with this condition due to the risk of pupil dilation. Regulatory documents do not provide a specific restriction or statement about its use in open-angle glaucoma.


Q: What should I do if I miss a dose of Propantheline?

A: Regulatory guidance states that if a dose is missed, it should be skipped if it is almost time for the next scheduled dose. The guidance also advises against taking a double dose to compensate for a missed dose.


Q: What are the official indications for Propantheline?

A: According to official regulatory labeling, Propantheline is indicated for use as adjunctive therapy in the treatment of peptic ulcer disease.


Q: Can I drink alcohol while taking Propantheline?

A: Official safety information states that consuming alcohol may increase the anticholinergic effects of the drug. These potential effects include increased drowsiness.

How should Propantheline be stored and disposed of?

Storage Conditions and Packaging

Propantheline bromide tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and kept in its original container, which should remain tightly closed to preserve the product's stability. All propantheline must be stored out of the reach and sight of children.


Official Disposal Instructions

To dispose of unused or expired Propantheline, the official recommendation is to utilize a local drug take-back program. If a take-back program is not available, the tablets may be discarded in the household trash. This requires mixing the medication with an unappealing substance, such as coffee grounds, placing the mixture in a sealed container, and then discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Propantheline found in:

A-Z Index: